IL-8's Indirect Role in Cancer
CXCL8 (IL-8) is a member of the cancer-related chemokine cluster and is upregulated by TNFa on MCF-7 cells [1]. CXCL8 plays a significant role in the immune system's response to inflammation and infection. While IL-8 itself does not directly cause cancer, it is involved in cancer in several ways:
|
Tumor Microenvironment: IL-8 is often overexpressed in many types of cancer, including breast, lung, and ovarian cancers. It plays a crucial role in shaping the tumor microenvironment by attracting immune cells, such as neutrophils, monocytes, and T cells, to the tumor site. These immune cells can have both pro-tumor and anti-tumor effects, depending on the context.
Angiogenesis: One of the critical roles of IL-8 in cancer is its involvement in angiogenesis, the process by which new blood vessels form. Tumors require a blood supply to grow and spread, and IL-8 can stimulate the growth of blood vessels, providing tumors with the nutrients and oxygen they need to thrive. Metastasis: IL-8 has been implicated in cancer metastasis, the spread of cancer cells from the primary tumor to distant sites in the body. It can enhance the invasiveness and migration of cancer cells, making it easier for them to break away from the primary tumor and establish secondary tumors in other organs. |
Immune Suppression: In some cases, IL-8 can contribute to immune suppression within the tumor microenvironment. It can attract immune cells with immunosuppressive properties, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). These immune cells can inhibit the body's natural anti-tumor immune response.
Resistance to Therapy: IL-8 has also been associated with resistance to certain cancer therapies, such as chemotherapy and radiation therapy. It can promote the survival of cancer cells and protect them from the cytotoxic effects of treatment.
Resistance to Therapy: IL-8 has also been associated with resistance to certain cancer therapies, such as chemotherapy and radiation therapy. It can promote the survival of cancer cells and protect them from the cytotoxic effects of treatment.
Given the multifaceted role of IL-8 in cancer progression and its potential impact on treatment outcomes, it has become a target of interest in cancer research. Scientists are exploring various strategies to block IL-8 signaling or interfere with its functions in the tumor microenvironment. These efforts aim to develop new therapeutic approaches to inhibit angiogenesis, reduce metastasis, and enhance the effectiveness of existing cancer treatments.
It's important to note that IL-8 is just one of many factors involved in cancer development and progression. The specific role and significance of IL-8 in cancer can vary depending on the type of cancer and individual patient characteristics. Ongoing research continues to shed light on the complex interplay between IL-8 and cancer, with the hope of uncovering new strategies for cancer prevention and treatment.
It's important to note that IL-8 is just one of many factors involved in cancer development and progression. The specific role and significance of IL-8 in cancer can vary depending on the type of cancer and individual patient characteristics. Ongoing research continues to shed light on the complex interplay between IL-8 and cancer, with the hope of uncovering new strategies for cancer prevention and treatment.
References
1. Leibovich-Rivkin, Tal, et al. "The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells." BMC cancer 14.1 (2014): 158. Article Link
2. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. "Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer." Int J Cancer 2012, 130(8):1733-1744. PubMed Abstract | Publisher Full Text |PubMed Central Full Text
3. Carlos Eduardo Coral de Oliveira, Julie Massayo Maeda Oda, Roberta Losi Guembarovski, et al., “CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer,” Disease Markers, vol. 2014, Article ID 126954, 8 pages, 2014. doi:10.1155/2014/126954 Article Link
1. Leibovich-Rivkin, Tal, et al. "The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells." BMC cancer 14.1 (2014): 158. Article Link
2. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. "Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer." Int J Cancer 2012, 130(8):1733-1744. PubMed Abstract | Publisher Full Text |PubMed Central Full Text
3. Carlos Eduardo Coral de Oliveira, Julie Massayo Maeda Oda, Roberta Losi Guembarovski, et al., “CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer,” Disease Markers, vol. 2014, Article ID 126954, 8 pages, 2014. doi:10.1155/2014/126954 Article Link
